Intratumor heterogeneity (ITH) drives neoplastic progression and therapeutic resistance. We used the bioinformatics tools 'expanding ploidy and allele frequency on nested subpopulations' (EXPANDS) and PyClone to detect clones that are present at a ≥10% frequency in 1,165 exome sequences from tumors in The Cancer Genome Atlas. 86% of tumors across 12 cancer types had at least two clones. ITH in the morphology of nuclei was associated with genetic ITH (Spearman's correlation coefficient,  = 0.24-0.41; P < 0.001). Mutation of a driver gene that typically appears in smaller clones was a survival risk factor (hazard ratio (HR) = 2.15, 95% confidence interval (CI): 1.71-2.69). The risk of mortality also increased when >2 clones coexisted in the same tumor sample (HR = 1.49, 95% CI: 1.20-1.87). In two independent data sets, copy-number alterations affecting either <25% or >75% of a tumor's genome predicted reduced risk (HR = 0.15, 95% CI: 0.08-0.29). Mortality risk also declined when >4 clones coexisted in the sample, suggesting a trade-off between the costs and benefits of genomic instability. ITH and genomic instability thus have the potential to be useful measures that can universally be applied to all cancers.
Cancers are a mosaic of clones with varying population sizes, different genetic makeups and distinct phenotypic characteristics [1] [2] [3] [4] . This intratumor heterogeneity provides the fuel for the engine of natural selection that drives the processes of carcinogenesis and acquired therapeutic resistance in neoplasms 1, 5 . When analyzing genome-sequencing data derived from single-tumor samples, it is important to recognize that, technically, sequences obtained from each tumor sample encode a tumor metagenome, as they represent the aggregate genomes of all of the clones that coexist within the sample [6] [7] [8] [9] [10] . Recently, McGranahan et al. 6 used exome-sequencing data derived from single-tumor samples to determine the clonal status of known, actionable drivers across nine cancer types and to identify events that trigger clonal expansions, causing ITH. However, the availability of just one sample per tumor and moderate sequencing depth have limited the opportunities for the systematic analysis of both the extent and the clinical consequences of ITH in previous pan-cancer studies 3, 7, [10] [11] [12] [13] [14] . To overcome these limitations, a variety of different algorithms have been developed to deconvolute tumor metagenomes. These algorithms estimate the cellular prevalence of mutations and quantify ITH [15] [16] [17] [18] [19] . We leveraged two of these tumor mixture-separation algorithms, EXPANDS 18 and PyClone 17 , to quantify ITH from exome-sequencing data in The Cancer Genome Atlas (TCGA) and to validate the robustness of our results.
RESULTS

Intratumor genetic heterogeneity exists in all tumor types
We measured the number and size of genetically diverse clones of 1,165 primary tumor samples across 12 cancer types from TCGA, using exome sequencing data from paired tumor-normal samples. These samples originated from a single sequencing center (Broad Institute, Cambridge, Massachusetts, USA) and were chosen because they fulfilled established, strict criteria to obtain uniform sequence data quality and depth (Supplementary Fig. 1 ). As clone detection sensitivity is highly dependent on the depth and breadth of genomic sequencing coverage, these criteria are necessary to ensure that measures of ITH that are derived from these sequences are comparable. Detailed inclusion criteria are available in Supplementary Note 1.
Somatic single-nucleotide variants (SNVs) and copy-number variants (CNVs) were called using MuTect 20 and ExomeCNV 21 , respectively ( Supplementary Fig. 2 ). We distinguished nonsynonymous SNVs and splice site-or regulatory-region SNVs (generally referred to as nonsilent) from synonymous SNVs and SNVs within intergenic and intronic regions (also referred to as silent). The incidence of CNVs and somatic nonsilent SNVs varied considerably within and between tumor types (Fig. 1a-c) , similarly to results obtained from other genome-wide sequencing studies 11, 22, 23 .
EXPANDS was applied to all detected somatic SNVs (including silent SNVs), and loss-of-heterozygosity (LOH) and copy-number estimates to infer the number, size and genetic content of subpopulations 1 0 6 VOLUME 22 | NUMBER 1 | JANUARY 2016 nature medicine of cells that coexist in the tumor (Fig. 1d) . Briefly, EXPANDS models the cellular prevalence of each SNV as a copy-number-dependent probability distribution. Subsequently, these cellular prevalence distributions are clustered to obtain the genetic content of each subpopulation, i.e., the set of SNVs and CNVs that accumulated in ancestral cells before each clonal expansion. Previous results 18 indicate that the sequencing data available per tumor (on average 5,221 Mb of reads) translates to an accuracy of 50-80% at which EXPANDS detects genetic heterogeneity at a macroscopic resolution 24 (i.e., clones present in ≥10% of the sample). An independent algorithm, PyClone, was used to validate the conclusions derived from EXPANDS. PyClone infers the cellular prevalence of SNVs differently from EXPANDS. In particular, PyClone does not model subclonal CNVs, and it leverages high depth rather than high breadth of sequencing 17 
(Supplementary Note 2).
In general, the cellular prevalence of SNVs assigned by PyClone and EXPANDS was concordant for SNVs located within genomic regions of clonal copy number (for which all tumor cells have identical ploidy) (ρ = 0.77). However, for regions in which CNVs affect only a subset of tumor cells, EXPANDS and PyClone tended to make different inferences for the cellular prevalence of SNVs within those regions (ρ = 0.25; Supplementary Note 2).
Subpopulations detected within the same tumor sample may have sizes that cumulatively exceed 100%, as a subpopulation may be nested in a parental population that carries earlier mutations. Both algorithms detect such nested subpopulation compositions. We refer to these inferred subpopulations as clones and to the cellular prevalence of a subpopulation within the tumor sample as its clone size. We denote the total number of clones detected within a tumor sample as the clone number. As noted previously, we define the term 'tumor metagenome' as the aggregate genomes of all coexistent clones within a tumor.
Assuming a monoclonal tumor origin, the largest inferred clone in each sample harbors the founder mutations (also referred to as 'trunk mutations') and corresponds to the first (founder) clonal expansion. This holds true regardless of the fitness difference between the founder and descending clones. The cellular prevalence of founder mutations will always be greater than or equal to the cellular prevalence of mutations acquired by descendant subclones, even if these later subclones proliferate faster than the founder cells. This implies that the size of the largest clone (i.e., the founder clone) is also a measure of tumor purity (Fig. 1e) ; this was confirmed by an independent study that compared the performance of EXPANDS to four other methods that predict tumor purity 25 . The size of the largest clone was correlated to tumor purity as predicted from expression profiling using ESTIMATE 26 (EXPANDS: Pearson coefficient of correlation, r = 0.43; P < 1 × 10 −6 ; PyClone: r = 0.63; P < 1 × 10 −6 ; Supplementary Fig. 3a) . Low-grade glioma n = 166 We observed that the number of somatic SNVs in large clones correlated with age at diagnosis (ρ = 0.3; P < 1 × 10 −6 ), a result previously reported for chronic lymphocytic leukemia (CLL) 8 . In addition, the number of SNVs in small clones also correlated with age (ρ = 0.18; P = 5 × 10 −6 ; Supplementary Fig. 3b,c) .
We compared the extent of genetic ITH across and within tumor types ( Fig. 2a-d) . The difference in the number of clones harbored between tumor types was similar before and after correcting for tumor purity ( Fig. 2c; see Online Methods). On average, four clones were estimated to coexist in a tumor at the time of biopsy or surgical resection (the median estimated number of clones was five by using EXPANDS and three by using PyClone; Fig. 2a,b) . There was a median of 10 (EXPANDS estimate) to 16 (PyClone estimate) nonsilent somatic SNVs per clone, and the distribution of clone sizes across tumor types was relatively uniform. Notably, reduced detection sensitivity (because of low tumor purity) was not sufficient to explain the smaller number of clones that were observed in low-purity tumors (Fig. 2e-h and Supplementary Note 3) .
In 14% (EXPANDS estimate) to 20% (PyClone estimate) of the analyzed tumor samples, only a single, genetically homogeneous cell population was detected. Even for thyroid carcinoma, the least heterogeneous tumor type, two or more clones were predicted to coexist in >50% of the samples (EXPANDS estimate: 52%; PyClone estimate: 65%). Therefore, we concluded that genetic ITH occurs in the vast majority of cancers represented among the 12 types that we included in this study.
Driver genes are mutated in clones of characteristic sizes To investigate the influence of the incidence of driver gene mutations on genetic ITH, we analyzed 259 cancer-driver genes (hereafter referred to as 'CAN genes'; Supplementary Table 1) . A gene was deemed to be substantially associated with a given cancer type on the basis of: (i) prior experimental evidence, (ii) the frequency of gene mutations in our sample cohort and (iii) mutation deleteriousness (see Online Methods). We found 124 non-private CAN genes (48%) that are mutated in a minimum of two cancer types (Fig. 3a) . We refer to a clone with one or more nonsilent mutations in any given CAN gene as a 'CAN clone' .
Next, we tested whether CAN clones differed in size depending on which CAN genes are mutated in the corresponding clones. The size of a clone depends on its selective fitness (how fast it expands relative to the other clones within a tumor) and on its formation time (when the underlying clonal expansion started). CAN-gene SNVs specific to a given clone may therefore have a direct impact on its size. To test this possibility, we first normalized clone sizes by tumor purity. We then calculated the mean and variance in clone size among all CAN clones and compared them to the variance calculated from random samples of clone sizes from our data ( Supplementary Fig. 4) .
The size of clones harboring CAN-gene mutations varied across the CAN genes (Fig. 3a) and was correlated to both the relative order of driver-gene mutations reported in earlier studies 11, [27] [28] [29] [30] and the clone sizes predicted by PyClone (0.43 < r < 0.94; 3.4 × 10 −18 < P < 0.12; Supplementary Fig. 5 ). Across tumor samples, and even across tumor types, CAN genes were often mutated in clones of a characteristic size, i.e., the variance in clone size was significantly lower than that expected by chance (one-sided t-test: P < 0.05; Fig. 3a) . For example, TP53 SNVs were found in larger clones (EXPANDS: 0.811 average cancer-cell fraction; PyClone: 0.746 average cancer-cell fraction) in all nine cancers that are significantly associated with genetic aberrations Melanoma (54) Bladder (114) Cervical (33) Stomach (146) Head and neck (165) Lung (squam) (87) Prostate (93) Glioblastoma (105) Kidney ( BRAF  TP53  NCOA3  PTEN  GPI  CADM1  SOD2  TAP2  RB1  CTNNB1  PIK3CA  SMAD4  PIK3CB  NF1  CD82  BRCA2  GFAP  CCNE1  TEK  EGR1  LAMA5  CYP4B1  AKT1  CP  XRCC1  MME  AXL  PTCH1  CTTN  HIF1A  ABCB1  CDH17  COL18A1  MUC4  CDKN1A  NRAS  ERBB2  MUC16  A2M  HLA-B  PTGS1  PTPRC  PRDM2  IGF1R  NOS3  VWF  DDC  PRKCA  STAT 3  MMP14  NCAM1  ITGAL  THBS1  DPP4  CDH1  CA9  ACTB  TP63  XDH  JUP  DLC1  MLH1  KRT8  OGG1  LRP1  KRT5  NOS1  FLT4  MTHFR  EGF  EPHA2  KDR  EGFR  FLT1  APC  MK167  HSPA1A  DAPK1  NTRK1  EPHB4  DPYD  MMP11  IL4R  TNE  MMP9  CEACAM5  ABCC1  DCC  GLI1  CDH3  ANPEP  EDNRB  SLC2A3  CTSD  APAF1  PIK3CG  ENO2  MAPK1  MVP  WT1  PTGS2  DMBT1  XRCC5  FGFR2  NOS2  HDC  TG  HGF  ANGPT1  MSH6  MUC5B  FAP  VCAM1  HSP90AA1  NRP1  FASN  ESR2  HLA-A  MMP2  CHEK2  ICAM1  BMP6 Pairwise similarity between tumor types was calculated as a Spearman correlation (**P < 0.01, *P < 0.05) on the basis of results from EXPANDS (above diagonal) and PyClone (below diagonal) analyses. (e) Partial dependency of clone number on SNV incidence. The number of clones identified in a sample depends on SNV incidence, but not all SNV categories are equally associated with the resulting number of clones. Nonsilent SNV incidence in CAN genes (red; mean = 2 genes) explains the variability in clone number (measured as coefficient of determination (R 2 ) ; x axis) better than the incidence of silent SNVs in CAN genes (yellow; mean = 1 gene) or of nonsilent SNVs in non-CAN genes (cyan; mean = 128 genes). **P < 0.01, *P < 0.05; log-likelihood test. in TP53. In contrast, somatic SNVs in DMBT1 were found in smaller clones (EXPANDS: 0.641 average cancer-cell fraction; PyClone: 0.652 average cancer-cell fraction) of the three cancers in which DMBT1 was among the drivers (Fig. 3a) . For a subset of CAN genes, however, we found substantial differences in the dominance of mutated clones, depending on cancer type. For example, clones with ERBB3 mutations were larger in bladder cancer than they were in any other cancer type, whereas clones with PTEN mutations grew particularly large in glioblastoma (Fig. 3b) . Clones with SNVs in CAN genes that are druggable (n = 98) did not have significantly different sizes as compared to clones with SNVs in the remaining CAN genes (n = 161; P = 0.77, Student's t-test).
Furthermore, clone size inferiority of a mutated CAN gene (as shown in Fig. 3a) was correlated to the propensity of the CAN gene as a risk factor (EXPANDS: P = 3.2 × 10 −7 , HR = 2.86; PyClone: P = 0.005, HR = 1.67; univariate Cox model). For instance, mutations in CAN genes that occurred in clones with average clone sizes in the bottom 5% of all CAN clone sizes were associated with poor outcome (Fig. 3c) . This relation was also significant in low-grade gliomas (EXPANDS: P = 1.60 × 10 −3 , HR = 4.04; PyClone: P = 0.24, HR = 1.77), kidney carcinoma (EXPANDS: P = 0.02, HR = 5.92; PyClone: P = 0.04, HR = 3.48) and glioblastoma (EXPANDS: P = 0.04, HR = 2.27; PyClone: P = 1.62 × 10 −3 , HR = 3.84; Supplementary Table 2 Representative images with outlined nuclei (a; bottom) and quantification of nuclear variability from the H&E-stained images (b) using CellProfiler (red bars) are shown. Black arrows represent the bladder cancer specimens shown in a. Error bars show the median absolute deviation of nuclear diversity rankings on the basis of measurements of three different descriptive aspects of nuclear size and staining intensity. Independent ranking of intratumor nuclear diversity across these 17 bladder cancer specimens by an expert histopathologist (blue bars) validates the automated nucleardiversity measures (ρ = 0.62; P = 0.009). In a, scale bars, 100 µm (left), 200 µm (right). (c) Violin plots of nuclear diversity within tumor types. Nuclear diversity was normalized to account for differences in tumor purity. Tumor types were ordered according to the extent of genetic ITH (Fig. 2b) . Tables 1 and 3) . Next, we used the size rankings of CAN clones to compare cancer types (Fig. 3d) . We measured whether a given CAN gene that is substantially associated to >1 cancer type is mutated in clones of similar sizes, regardless of cancer type. Head and neck cancer, low-grade glioma and glioblastoma showed significant similarities in CAN clone sizes with those of most of the other cancer types (0.12 ≤ ρ ≤ 0.43; P < 0.05), although all cancers shared their CAN clone-size signature with at least one other cancer type ( Fig. 3d ; PyClone and EXPANDS: 0.12 ≤ ρ ≤ 0.58; P ≤ 0.05).
Finally, we tested whether distinct SNV categories differ in how well they model the number of detected clones per tumor. For each cancer type, silent SNVs in non-CAN genes accounted for 0-57% of the variability in the number of clones (on average 25%). Including silent SNVs in CAN genes as predictors of clone number did not improve the model. In contrast, including nonsilent SNVs in CAN genes improved the predictions, accounting for 30% of the variability in the number of clones (log-likelihood test: P < 0.05; Fig. 3e) . These results suggest that mutations driving clonal expansions are more common among nonsilent SNVs in CAN genes than among other SNV categories (see Online Methods and Supplementary Note 2).
Histologic ITH and proliferation rate reflect genetic ITH A standard histomorphologic metric of tumor differentiation is the variability in nuclear size and H&E staining, which facilitates comparisons across cancers independently of tissue origin. A total of 2,231 whole-slide images of H&E-stained tumor samples were available in TCGA for 930 (80%) of the analyzed tumor samples ( Supplementary  Fig. 2 ). To quantify histologic ITH from these images, we measured the variabilities in nuclear size and staining intensity (Supplementary Note 4). For each tumor, the established image-analysis software CellProfiler 31 was used to measure the size and staining intensity of every nucleus detected in the tumor's H&E-stained images 32, 33 . A histopathologist conducted an independent scoring in a blinded fashion of a subset of 17 images of H&E-stained tumor samples (Supplementary Fig. 6 ), which confirmed the accuracy of the nuclear diversity as scored by CellProfiler (ρ = 0.62, P = 0.009; Fig. 4a,b) .
The extent of nuclear ITH varied between tumor types (Fig. 4c) ; greater nuclear diversity was observed with a greater number of clones detected in a tumor sample (Fig. 4d) in kidney cancer (ρ = 0.413; false-discovery rate (FDR)-adjusted P = 0.004), stomach cancer (ρ = 0.406; FDR-adjusted P = 2.97 × 10 −4 ), head and neck cancer (ρ = 0.278; FDR-adjusted P = 0.009), bladder cancer (ρ = 0.246; FDR-adjusted P = 0.022) as well as across all 12 cancer types (ρ = 0.243; FDR-adjusted P = 8.15 × 10 −13 ). Increased nuclear diversity with increasing clone number was observed for both PyClone-and EXPANDS-based clone number predictions, as well as after normalizing nuclear and genetic ITH measures to account for tumor purity (Supplementary Table 4 and Supplementary Fig. 7) . We used the mRNA expression level of the proliferation marker Ki67, which was available for 854 (73%) of the samples, as a measure of a tumor's average proliferation rate 34 . Clone number was significantly correlated to Ki67 expression within low-grade glioma (ρ = 0.18; P = 0.021) and prostate cancer (ρ = 0.21; P = 0.046) as well as across cancers (ρ = 0.31; P = 2.69 × 10 −20 ). However, tumor type-specific P values did not remain significant after FDR correction for multiple-testing (P > 0.05). For a subset of cancer types (the three squamous cell carcinomas of the head and neck, lung and cervix, respectively), very heterogeneous tumors (with >8 clones) had low Ki67 expression (Supplementary Fig. 8) .
Overall, these results show that nuclear and cellular features typically associated with aggressive disease correlate with greater genetic ITH across cancer types. . Untreated individuals (left) had an especially favorable outcome when these few clones shared a large CNV burden (blue continuous line). This was not the case for treated individuals (right). All hazard ratios were calculated with log-rank tests (**P < 0.005; *P < 0.05; • P < 0.1). For each stratum in panels a,b,e, at least 50% of the 12 analyzed tumor types were represented at >5% frequency. Table 7) . When considering each cancer type separately, no significant monotonic association between clone number and survival was evident (P > 0.05; Supplementary Table 2), except for gliomas (EXPANDS: P = 0.03, HR = 3.25; PyClone: P = 0.04, HR = 2.34). Across cancer types, the presence of more than two clones was associated with worse overall survival as compared to tumors in which either one or two clones were detected (EXPANDS: P = 8.6 × 10 −4 , HR = 1.49; PyClone: P = 0.09, HR = 1.21; log-rank test; Fig. 5a and Supplementary Fig. 9) .
The association between clone number and survival was nonlinear. An increased risk with increasing clone number was observed only for tumors with up to four clones. Additional diversification (>4 clones) did not impart further risk. In fact, a tendency for reduced risk was observed among highly diverse tumors. This risk reduction did not reach significance in the univariate analysis ( Supplementary  Fig. 10a ), although it was significant in the multivariate analysis (described below). The nonlinear relationship between ITH and survival was also apparent when using alternative measures of ITH (such as nuclear diversity or accounting for differential tumor purity; Supplementary Fig. 10b-d) .
A measurement of genomic instability is the fraction of the tumor metagenome that is affected by CNVs (CNV abundance) 35 . Because genomic instability correlates with ITH ( Supplementary Fig. 10e) , we hypothesized that the increased genomic instability necessary to produce a high level of ITH (i.e., >4 detected clones) could adversely affect tumor-cell fitness after the generation of deleterious CNVs. We therefore analyzed the impact of somatic CNV abundance in the tumor metagenomes and its relation to ITH. We found that, across cancer types, low or high CNV abundance-i.e., CNVs affecting either a very low or a very high fraction of the tumor metagenome-was predictive of improved survival (P = 5 ×10 −6 , HR = 0.15; log-rank test; Fig. 5b ). This was not the case for low or high somatic SNV abundance (FDR-adjusted P > 0.05; Supplementary Table 6 ). We validated this result with CNVs measured using genome-wide SNP arrays from the same tumor samples and from an independent data set consisting of 2,010 tumor samples across seven distinct cancer types. Both validation analyses confirmed that intermediate CNV abundance is associated with poor survival ( Supplementary  Fig. 11 and Supplementary Table 8) .
The highest risk was observed among individuals in whom 50-75% of the tumor metagenome was affected by CNVs in both the original and the independent data sets ( Fig. 5c and Supplementary  Fig. 11a,b) . In fact, tumors with 50-75% CNV abundance did represent the highest risk group among individuals with bladder cancer, head and neck cancer, lung adenocarcinoma, stomach adenocarcinoma, cervical cancer and low-grade gliomas (Supplementary Fig. 12 ). These observations suggest the existence of an optimal degree of genomic instability that is independent of tumor type.
Of the 12 tumor types, glioblastoma was the only cancer for which >75% CNV abundance was associated with the worst prognosis (Supplementary Fig. 12g) . Notably, 85% of individuals diagnosed with glioblastoma undergo chemo-and/or radiotherapy; thus, DNAdamaging therapy is administered more frequently for glioblastoma than for any of the other analyzed tumor types (Supplementary Table 7 ). Therefore, we verified whether or not adjuvant chemo-or radiotherapy affected the nonlinear association between CNV abundance and survival. In contrast to the 643 individuals who did not undergo chemo-or radiotherapy, the association between intermediate CNV abundance and poor survival was not significant among the 514 individuals treated with DNA-damaging agents (Fig. 5d) . This finding was confirmed in the independent SNP-array data set, in which tumors with intermediate CNV abundance did represent the highest-risk group among untreated individuals but not among those treated with chemo-or radiotherapy (Supplementary Fig. 11c,d) .
A tumor with a critical level of >75% CNV abundance per tumor metagenome may either be composed of many clones with low levels of CNV abundance per clone or of a few clones, each with high levels of CNV abundance (Supplementary Fig. 13 ). We used a clone number of 2 and a CNV abundance of 75% as thresholds to stratify untreated individuals into four groups as follows: (i) CNV abundance ≤75% and a maximum of two clones; (ii) CNV abundance ≤75% and a minimum of three clones; (iii) CNV abundance >75% and a maximum of two clones; and (iv) CNV abundance >75% and a minimum of three clones. The overall survival between individuals of these four groups was significantly different (EXPANDS: P = 0.0015; HR = 1.4; log-rank test). In general, and consistent with our previous observations, a low clone number was associated with a good outcome. In particular, the best outcome among the four groups was observed when a high CNV burden was shared among ≤2 clones (group (iii); Fig. 5e and Supplementary Fig. 9 ). After similarly stratifying individuals who had undergone chemo-and/or radiotherapy, we observed that differences in clone number, rather than CNV burden, were associated with differences in overall survival between individuals of the four groups (EXPANDS: P = 0.038, HR = 1.4; log-rank test; Fig. 5e ). Stratification of tumors on the basis of PyClone-derived clone numbers also supported these conclusions, although with borderline significance (P ≤ 0.07; Supplementary Fig. 9a) .
To account for factors that may confound the associations observed between clinical outcome and genetic ITH, the prognostic significance of clone number and low or high CNV abundance was evaluated using multivariate Cox models (see Online Methods). All tumor types were included in a pan-cancer Cox model, except for gliomas-as the staging system is not applicable to gliomas. Across cancers, both npg genomic instability and genetic ITH remained significantly associated to survival in the multivariate setting ( Table 1) . As concluded from the univariate analysis ( Supplementary Fig. 10a,b) , the relationship between clone number and survival was nonlinear: an increased risk with increasing clone number was only observed for up to four clones. Additional diversity (>4 clones) was associated with an increase in overall CNV burden and a significant decrease in the risk of mortality (Supplementary Fig. 10e,f) . A similar scenario was observed within eight of the ten analyzed cancer types, in which the highest hazard was associated with an intermediate number (between three and five) of clones. ITH levels above or below an intermediate number of clones were associated with significantly reduced risk (multivariate Cox: HR = 0.01-0.21, P ≤ 0.05) relative to that of the intermediate groups for head and neck cancer, melanoma and kidney cancer ( Supplementary  Fig. 10g and Supplementary Table 9 ).
DISCUSSION
Quantification of ITH is a key measure of tumor evolution. We performed a cross-sectional analysis of ITH in 1,165 cancers from 12 cancer types, revealing the extent of ITH and supporting its potential as a universal, although perhaps nonlinear, prognostic biomarker. Evidence from two tumor mixture-separation algorithms and from H&E-imaging analysis collectively indicates that ITH is a feature of the vast majority of diagnosed cancers. To our knowledge, this is the first report of a cross-cancer correlation between genetic ITH and histopathologic ITH, suggesting that measurements from H&E-stained tumor sections can provide a proxy for genetic ITH. Currently, single-tumor samples provide the only opportunity to study genetic ITH in a large pan-cancer cohort. Measuring ITH from single-tumor samples benefits from high depth and high genomic breadth of coverage. At TCGA, the best trade-off between these two sequencing-design parameters becomes manifest in exome-sequencing data. Using exome-sequencing to quantify ITH implies that clone distinction is confined to coding regions, and thus two clones differing in only noncoding regions would be indistinguishable using this approach. Whole genomes sequenced at a higher depth and the availability of multiple samples from different geographical regions of a tumor will further improve the sensitivity in detecting small clones and will increase our ability in resolving the clonal composition of tumors and its variability across cancer types.
Our results showed that mutations in particular driver genes are associated with clones of a characteristic size, often independently of tumor type. This observation suggests that there are constraints on the order in which neoplastic cells acquire driver events 36 or that these events differ in the magnitude of the fitness advantages they provide to neoplastic cells (Fig. 3a) . Small clones may be fit but evolve late in tumor progression. Alternatively, these clones may be less fit but can function as a 'cornucopia of evolution' from which new clones frequently emerge. Both alternatives explain why these clones are so small and why their presence is associated with poor outcome (Fig. 3c) . Notably, the number of mutated CAN genes did not predict outcome, suggesting that the relation between the survival and presence of small clones was not confounded by the incidence of mutations in the CAN genes.
The significant association between a high clone number and the poor survival detected in the combined analysis of low-grade glioma and glioblastoma is interesting in the context of the highly variable clinical behavior of low-grade gliomas. A recent study found that histopathologic classification may overlook a subset of glioblastoma tumors and label them as low-grade gliomas 37 . Thus, knowing the extent of ITH may help improve the differential diagnosis between glioblastoma and low-grade glioma.
As previously observed in ovarian, gastric, non-small cell lung cancers and estrogen receptor (ER)-negative breast cancers 38, 39 , individuals with intermediate CNV burdens detected in their primary, untreated tumor had the worst overall survival. We find this association to be present across several tumor types; however, the strength of the association varies with the type of adjuvant therapy the individuals received subsequently to surgery. Our results suggest a potential advantage when tumors with intermediate levels of CNVs are treated with adjuvant chemo-and radiotherapy (Fig. 5d) . Chemo-and radiotherapy may be particularly effective against tumors with intermediate CNV burdens by pushing them past the limit of 'tolerable' genomic instability. Our results from two distinct high-throughput technologies that measured CNV abundance in two independent pan-cancer cohorts suggest that this tolerance limit is exceeded when >75% of a tumor's metagenome is affected by CNVs, independently of cancer type. Because >37% of cancers have been shown to undergo whole-genome doubling events 10 , it will be of interest to see whether these tumors have the same phenotype as tumors with a >75% CNV burden.
In light of recent evidence supporting a stronger role for CNVs rather than SNVs in developing and maintaining ITH 9 , this upper limit of tolerable genomic instability may be responsible for the nonlinear association that we observed between genetic ITH and survival. Previous studies have shown that low ITH is predictive of favorable prognosis in head and neck cancer 9 , leukemia 8, 40 as well as in Barrett's esophagus 41, 42 , a premalignant condition. Consistent with these studies we found that the presence of only one or two clones is, in general, prognostic of a favorable outcome, especially when these few clones share a high CNV burden. However, diversification beyond four clones was also associated with a favorable outcome.
Individuals with high ITH may have a favorable outcome because a large number of clones can attract more immune cells. Alternatively, the observation may be, in part, because of the technical difficulty in distinguishing between ITH and genomic instability, in particular as both measures increase. Finally, the favorable outcome may be a consequence of a trade-off that exists between the chance of acquiring an advantageous alteration that initiates a new clonal expansion and the risk of generating inviable daughter cells. The observed synchronous increase in ITH and CNV burden suggests that efforts aimed at modulating this trade-off may represent a new therapeutic avenue to slow tumor evolution and improve clinical outcomes.
METHODS
Methods and any associated references are available in the online version of the paper. 
ONLINE METHODS
Copy-number and somatic point-mutation profiles. To calculate copynumber segments we used a circular binary segmentation approach optimized for exome-sequencing input data 21 and excluded regions of low sequencing depth (≤30-fold). Somatic point mutations for each tumor sample were obtained with Mutect 43 , and LOH was evaluated with JointSNVMix 44 , on the basis of the tumor-derived BAM file and the matched normal BAM file. Genomic point mutations were annotated with Oncotator version 1.2. The settings that were chosen for all of the programs are noted in Supplementary Figure 2 .
The choice of estimating copy number from exome-sequencing rather than SNP-array data was guided by: (i) the guaranteed consistency of clonal proportions between SNV and CNV data sources and (ii) the priority of having high resolution of copy numbers within exonic regions over noncoding regions. For (i), as digital signals from SNVs and CNVs are integrated to infer clonal compositions, the consistency of clonal proportions across these two data sources is critical. Estimating both copy number and SNVs from sequencing data rules out the presence of any experimental variability in the proportion of clones between the CNV and SNV data sources. For (ii), the vast majority of clonal analysis algorithms rely only on the copy-number information at loci with detected SNVs, i.e., for exome-sequencing data, within exonic regions. Although estimating copy numbers from exome sequencing leaves us blind to breakpoints in-between exons, within exonic regions it provides more 'dense' information than does SNP data 45 . For our analysis, exome-CNV calls were better suited and more precise for determining copy-number-overlapping somatic SNVs.
Inference of genetic ITH using EXPANDS. The EXPANDS version 1.4 software was used with default parameters to infer clonal subpopulations of tumor cells 46 . SNVs located within allosomes or within mitochondrial genomes were excluded. SNVs that could not be explained by a clone present in 10% or more of the sample, at a ploidy of six or less, were also excluded. For example, a SNV measured at an allelic frequency of 0.04 cannot be explained by a clone present in ≥10% of the sample, unless we assume that the high-level amplification of the wild-type allele dilutes the signal of the mutated allele. Finally, in 40.5% of tumors we found homozygous deletions affecting on average 1.5% (95% CI: 0-6.5%) of the tumor metagenome. Because a tumor cell cannot harbor both a point mutation and a homozygous deletion within the same genomic region and because EXPANDS requires both signals, these regions could not be used for inferring clonal composition. The remaining detected copy-number segments and SNVs were used to predict the number of clones that coexisted in each tumor sample, the clone size, clone-specific mutations and tumor phylogeny. Tumor phylogeny predictions were unavailable for tumor samples in which EXPANDS inferred only one single clone (n = 160) and unsuccessful for samples with insufficient CNVs in the tumor metagenome (n = 120). All other prediction aspects were available for all 1,165 tumor samples.
Inference of genetic ITH using PyClone. PyClone version 0.12.7 was used as an alternative and complementary approach to infer the clonal composition of each tumor sample. The same copy-number segments and SNVs described above were used as input, with the only modification being that the copy number of each segment was rounded to the closest integer value. Integer copy numbers are required by PyClone because the method does not model subclonal CNVs 47 . We took advantage of PyClone's flexibility in specifying prior probability estimates of possible mutational genotypes to model the uncertainty of the number of DNA copies affected by SNVs for each mutated locus. We modeled the number of SNV-harboring DNA copies for a given locus as a Poisson variable with the parameter λ S = 0.5 for somatic SNVs and λ LOH = 0.7 for germline SNVs within LOH regions. The probability that the SNV will affect a given DNA copy is higher for LOH, as an over-representation of the nonreference allele in the cancer cell relative to a normal cell is inherent to the definition of LOH 4 (see also Supplementary Note 2).
Quantification of nuclear ITH. CellProfiler was used to detect nuclei in representative H&E images for each tumor sample. Images processed by TCGA's centralized Biospecimen Core Resource were available for 930 tumor samples. Briefly, the nuclear diversity measure was obtained by ranking tumor samples according to the median absolute deviation (MAD) of nuclear radius and the MAD of nuclear staining intensity across detected nuclei. Image quality control and normalization steps (to account for variability in storage, handling and stain up-take) are described in Supplementary Note 4.
A subset of 17 individuals with bladder cancer who are representative of the full interval of measured nuclear diversity was randomly selected to validate the accuracy of nuclear-diversity measures obtained from automated image analysis. A total of 47 scanned H&E images were available for these 17 individuals at TCGA and were used to quantify nuclear diversity for each individual using CellProfiler.
Of these 47 images, 17 (one image per individual; Supplementary Fig. 6 ) were ranked according to ITH in nuclear intensity by a histopathologist (M.J.) who was blinded to the nuclear-diversity ranks estimated from the automated image analysis. Finally, the nuclear diversity rankings derived from histopathology analysis were compared to the diversity rankings obtained from the automated image analysis. Representative regions from H&E slides were visualized with OpenSlide 48 .
Code availability. The CellProfiler pipeline employed to detect and measure nuclei from H&E-stained images is available at http://dna-discovery.stanford. edu/projects/completed-projects/pan-cancer-ith.html.
Normalization of ITH measures to account for differences in tumor purity. Two linear regression analyses were used to model clone number and nuclear diversity, respectively, as a function of the percentage of tumor nuclei that were estimated from histopathological examination ('tumor purity'). The clone number and nuclear diversity measures were then normalized by subtracting the tumor purity-associated effects quantified in the linear regression analyses (see also Supplementary Fig. 7 ).
Selection of cancer-driver genes. Cancer-driver gene candidates (CAN genes) were selected by using three sources: (i) the mutation frequency analysis in our cohort; (ii) the Cancer Gene Index (CGI) resource that is provided by the National Cancer Institute (NCI), is derived from literature mining and estimates how strongly a gene is associated to a given type of cancer; and (iii) the Combined Annotation-Dependent Depletion (CADD) framework resource 49 , which quantifies the deleteriousness of SNVs by integrating various annotation resources into a so-called Phred C-Score. The Phred C-score is a ranking score assigned to each SNV that has been shown to strongly correlate with the pathogenicity of the SNV and with its experimentally measured regulatory effects. Altogether, a gene G was included as significantly associated with a given cancer type if three or more CGI entries confirmed that G has been experimentally associated with the cancer type and if at least three tumors of the respective type harbored somatic SNVs within the gene that have a deleteriousness score (Phred C-Score) ≥3. This integrated analysis yielded 259 CAN genes. The results presented in Figure 3 were robust to changes in the thresholds used in the various sources (i-iii) to define the CAN genes.
CAN gene stratification and functional annotation. We classified the 259 CAN genes on the basis of their mutation occurrence in small-sized (lower quartile), medium-sized (interquartile range) and large-sized (upper quartile) clones (Supplementary Table 1) . We used the functional annotation clustering program DAVID 50,51 on the gene sets defined by clone size. All reported P values were FDR-adjusted. The Drug-Gene Interaction Database 52 (DGIdb) was used to classify CAN genes as either 'druggable' (n = 98) or 'currently not druggable' (n = 161). The size of clones with CAN-gene mutations was calculated as an average across all 12 cancer types.
Modeling clone number from SNV accumulation. Linear regressions were fit to model the number of detected clones as a function of SNV accumulation. Four categories of somatic SNVs were analyzed as independent predictors of clone number: (i) nonsilent SNVs in CAN genes (total of 259 genes); (ii) silent SNVs in CAN genes; (iii) nonsilent SNVs in genes not included in the CAN-gene set (total of 23,782 genes); and (iv) silent SNVs in non-CAN genes. Four linear regression models were fitted for each cancer type as follows: the first model (M-0) used silent SNVs in non-CAN genes as an independent variable and number of clones as the dependent variable. For the other three models (M-1, M-2 and M-3), nonsilent SNV incidence in CAN genes, silent SNV incidence in CAN genes and nonsilent SNV incidence in non-CAN genes were, respectively, npg added as independent variables to M-0. Finally, likelihood-ratio-test statistics measuring the improvement of M-1, M-2 and M-3 over M-0 were calculated. MATLAB functions 'fitlm' and 'lratiotest' were used for model-fitting and for the likelihood-ratio tests, respectively. We note that clone detection by EXPANDS and PyClone does not rely on differences between SNVs in their potential to affect selective fitness (for example, by distinguishing between silent and nonsilent SNVs or by taking into account the identity of the target gene).
Quantitative measure of accumulation of mutations in CAN genes: the progression index. Because previous evidence suggests that driver genes are mutated in a predetermined sequential order during tumor growth 53, 54 , the incidence of driver -gene mutations detected in an individual can predict the degree of tumor progression.
Let G = {g 1 … g n } be the n driver genes previously derived for a given type of cancer, f g be the mean clone size among all clones with mutations in g across all tumors and G I  G be the subset of genes mutated in the tumor of an individual I. The progression index of an individual I diagnosed with a given cancer type was then calculated from the incidence of nonsilent mutations in driver genes (G I ): The measure focuses on those particular SNVs with the least amount of representation in the data set that are the most difficult to model accurately. However, because the inference of clonal composition is restricted to regions with adequate read coverage (Supplementary Note 1) , the measure is less prone to errors due to low sequencing coverage.
Testing the size variance of clones with nonsilent mutations in CAN genes.
For every CAN gene g, let k g be the number of clones harboring mutations in g and V g be the variance in the size of those clones. We further calculated the variance in clone size of k g clones randomly selected from the entire set of all detected clones and repeated this process 2,000 times, obtaining V R = {V 1 …V 2000 }. Finally we tested whether V g is lower than the 2,000 variances obtained from random samplings of clones (V R ) using a one-sided students t-test (MATLAB function 'ttest2'). Clone sizes were always calculated relative to the size of the founder clone for the purpose of this analysis. Variances V g were calculated across all tumors with mutations in g, independently of cancer type.
Quantitative measures of mutation burden: SNV abundance and CNV abundance. A tumor's mutation burden was calculated for each tumor from somatic SNVs and CNVs. First, SNV abundance was calculated as the count of nonsilent somatic SNVs. In addition, we quantified low and high SNV abundance measures for each tumor, T, as:
where M snv is the mean SNV abundance observed among all 1,165 analyzed tumors.
Second, the fraction of the genome affected by copy-number changes, a surrogate for chromosomal instability, was calculated from the copy-number segments, s, obtained by circular binary segmentation in the following manner.
Let C S and L S denote the absolute copy number and the total length of segment s, respectively. Furthermore, let f X be binary functions on C S , defined to calculate: (i) X = amplification abundance, (ii) X = deletion abundance and (iii) X = CNV abundance as follows: where t is a threshold reflecting the minimal deviation from the diploid copy-number status above which a segment is considered to be amplified or deleted. t = 0.25 was chosen, which corresponded to a cellular resolution on single-copy changes affecting ≥25% of the sequenced sample. The choice of the threshold was a compromise between low false-positive rates and high resolution on subclonal CNVs and corresponded to a resolution on subclonal single-copy changes present in at least 25% of the sample. For high-level amplifications the cellular resolution increases accordingly (for example, ≥13% for twofold amplifications). Copy changes affecting a smaller fraction of cells are increasingly difficult to distinguish from noise during circular binary segmentation (see also Supplementary Note 2). Then, the fractions of the tumor metagenome affected by amplifications, deletions and CNVs in general, are calculated as: pathologic stage in lung adenocarcinoma (P = 0.01). These exceptions have been flagged in Table 1 and Supplementary Table 9 .
The R package 'survival' was used to build the Cox models (function 'coxph'). The R package 'smoothHR' was used to plot the hazard ratios and to test the proportional-hazards assumption (function 'smoothHR').
Tumor stratification on the basis of ITH and CNVs. Four cut points were chosen for four distinct measures: (i) the average size of clones with mutations in CAN genes (see section on progression index); (ii) the CNV burden; (iii) the clone number; and (iv) the purity-normalized clone number. Each stratum resulting from the four chosen cut points was represented by at least 47 members. Results obtained by comparing the groups were robust to variable stratification thresholds. For measures (ii)-(iv), the magnitudes of the individual cut points were selected such that they marked the transition (in CNV burden and clone number, respectively), which is accompanied by the greatest change in hazard ( Fig. 5a-d) .
Statistical analyses. The chi-squared goodness-of-fit test (MATLAB function 'chi2gof ') was used to verify whether the data had a normal distribution. The two-sample F-test (MATLAB function 'vartest2') was used to verify whether the compared groups had equal variances. When the groups did meet the assumption of normality but did not meet the assumption of equal variances (as in Fig. 3b) , the test statistic under the null hypothesis had an approximate Student's t-distribution with a number of degrees-offreedom given by Satterthwaite's approximation (MATLAB function 'ttest2' with 'Vartype' option set to 'unequal'). If the compared groups did not meet either the assumption of normality or the assumption of equal variances, then the Kolmogorov-Smirnov test (MATLAB function 'kstest2') was used to test the null hypothesis that two samples were from the same continuous distribution.
Correlation coefficients. The Spearman correlation coefficient (ρ) was reported when at least one of the assumptions underlying the Pearson correlation (i.e., normal distribution, homoscedasticity or linearity) was not met. Otherwise we reported the Pearson correlation coefficient. Both correlation coefficients were calculated using the MATLAB function 'corr' .
